DVDeepa Viswanathan

Deepa Viswanathan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Deepa Viswanathan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sympathetic ophthalmia associated with untreated choroidal melanoma

    by Deepa Viswanathan, Ali S. Haider, Anthony Dunlop, David McKeag


  • Comparative study of long-term outcomes of accelerated and conventional collagen crosslinking for progressive keratoconus

    by J J Males, D Viswanathan

    To compare the long-term outcomes of accelerated corneal collagen crosslinking (CXL) to conventional CXL for progressive keratoconus. Comparative clinical study of consecutive progressive keratoconic eyes that underwent either accelerated CXL (9 mW/cm2 ultraviolet A (UVA) light irradiance for 10 min) or conventional CXL (3 mW/cm2 UVA light irradiance for 30 min). Eyes with minimum 12 months’ follow-up were included. Post-procedure changes in keratometry readings (Flat meridian: K1; steep meridian: K2), central corneal thickness (CCT), best spectacle-corrected visual acuity (BSCVA), and manifest refraction spherical equivalent (MRSE) were analysed. A total of 42 eyes were included. In all, 21 eyes had accelerated CXL (20.5±5.5 months’ follow-up) and 21 eyes had conventional CXL group (20.2±5.6 months’ follow-up). In the accelerated CXL group, a significant reduction in K2 (P=0.02), however no significant change in K1 (P=0.35) and CCT (P=0.62) was noted. In the conventional CXL group, a significant reduction was seen in K1 (P=0.01) and K2 (P=0.04), but not in CCT (P=0.95). Although both groups exhibited significant reductions in K2 readings, no noteworthy differences were noted between them (P=0.36). Improvements in BSCVA (accelerated CXL; P=0.22 and conventional CXL; P=0.20) and MRSE (accelerated CXL; P=0.97 and conventional CXL; P=0.54) were noted, however were not significant in either group. Accelerated and conventional CXL appear to be effective procedures for stabilising progressive keratoconus in the long-term.


  • Comparative analysis of corneal measurements obtained from a Scheimpflug camera and an integrated Placido‐optical coherence tomography device in normal and keratoconic eyes

    by Deepa Viswanathan, Nikhil L. Kumar, John J. Males, Stuart L. Graham

    Purpose: To assess the agreement between a Scheimpflug camera (Pentacam) and a combined Placido‐optical coherence tomography device (Visante OMNI) in measuring corneal curvature, thickness and elevation values in normal and keratoconic eyes.Methods: Corneal measurements of 110 normal eyes (one eye per subject) and 70 keratoconic eyes were obtained from both devices and compared. Agreement was determined using the Bland–Altman analysis 95% limits of agreement (LoA).Results: The Pentacam measured significantly greater keratometry readings in the flattest (K1) and steepest meridians (K2) in normal and keratoconic eyes. The 95% LoA in normal eyes were −0.32 to 0.59 dioptres (D) (K1) and −0.41 to 0.74 D (K2). In keratoconic eyes, the 95% LoA were −1.35 to 1.92 D (K1) and −1.38 to 1.99 D (K2). The Pentacam recorded significantly higher central corneal thickness (CCT) values in both groups of eyes. The 95% LoA were −4.31 to 39.89 microns (μ) and −12.92 to 41.35 μ in normal and keratoconic eyes, respectively. Pentacam anterior and posterior corneal elevations were significantly greater in both groups of eyes. The devices demonstrated excellent repeatability and reproducibility for corneal curvature and thickness but not elevation measurements.Conclusions: The Pentacam measured significantly greater corneal curvature, thickness and elevation values compared to the Visante OMNI in normal and keratoconic eyes. The devices agree moderately for anterior corneal elevations in normal eyes and do not appear to be interchangeable for corneal measurements in clinical practice.


  • Relationship of change in central corneal thickness to visual field progression in eyes with glaucoma

    by Deepa Viswanathan, Ivan Goldberg, Stuart L. Graham

    Background To assess the relationship between baseline central corneal thickness (CCT) and/or ongoing CCT change over time with subsequent visual field progression. Methods One hundred sixty three eyes of 163 patients with medically treated glaucoma were followed up for 6.8 ± 1.8 years. Exclusion criteria was laser or intraocular surgery. Baseline and follow up CCT, confocal scanning laser tomography and visual fields were performed. CCT and CCT change related to visual field progression using Glaucoma Progress Analysis were assessed. Multivariate logistic regression analysis for predictive factors of glaucoma progression was used to analyze data. Results Thinner baseline CCT was associated with more advanced damage at presentation, mean deviation (MD) (r = 0.17, p = 0.02) and neuroretinal rim area (NRR) (r = 0.20, p = 0.02). Progressing eyes had significantly thinner (p = 0.01) baseline CCT compared to non-progressing eyes. The slope of visual field change was significantly greater (p = 0.05) for thinner (p < 0.0001) was noted in all eyes; however, there was no significant difference (p = 0.95) in the amount of change between progressing and non-progressing eyes. CCT change did not correlate with MD or NRR change. A thinner CCT (Odds ratio = 1.80, p = 0.02), but not CCT change (Odds ratio = 1.07, p = 0.69), was a significant risk factor for glaucoma progression. Conclusions CCT correlates significantly with the amount of glaucomatous damage at presentation. Thinner corneas may be associated with increased risk of visual field progression. CCT reduced slightly over time in eyes with glaucoma; but the magnitude of this change was not related to visual field progression.


  • Longitudinal effect of topical antiglaucoma medications on central corneal thickness

    by Deepa Viswanathan, Ivan Goldberg, Stuart L Graham

    Background: To determine the change in central corneal thickness over time and whether the use of long‐term topical antiglaucoma medications influences central corneal thickness.Design: Case control study with retrospective and prospective data collection.Participants: One hundred eighty‐seven eyes of 187 glaucoma patients (mean follow up 6.92 ± 1.67 years) being treated with topical antiglaucoma medications (at least 3 years) with no history of surgery or laser were included and compared with 100 eyes of 100 age–matched, untreated control subjects (mean follow up 6.58 ± 1.93 years) who were glaucoma suspects with normal intraocular pressure not on any treatment.Methods: Demographic data, central corneal thickness and intraocular pressure were collected at initial glaucoma diagnosis and at most recent visit, and findings were compared between two groups.Main Outcome Measures: Mean change in central corneal thickness in microns (μm).Results: Central corneal thickness fell significantly (P < 0.0001) in treated eyes but not in control eyes (P = 0.18); mean central corneal thickness reduction was 12.29 ± 13.65 μm in treated eyes and 1.17 ± 8.75 μm in controls. Among treated eyes, central corneal thickness reduction was significant (P < 0.0001) in those treated with either prostaglandins or a combination of prostaglandin and beta‐blockers, while no significant reduction occurred in eyes treated with only beta‐blockers (P = 0.15) when compared with control eyes.Conclusions: Prostaglandins appear to be associated with a small but significant central corneal thickness reduction over time. Serial central corneal thickness measurements might be helpful in glaucoma patients, particularly those on prostaglandins.